These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22472511)

  • 1. The role of 5-alpha-reductase inhibitors in active surveillance.
    Margel D; Fleshner N
    Curr Opin Urol; 2012 May; 22(3):243-6. PubMed ID: 22472511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Alpha reductase inhibitors in active surveillance.
    Richard PO; Finelli A
    Curr Opin Urol; 2014 May; 24(3):324-8. PubMed ID: 24710052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI and surveillance.
    Ouzzane A; Puech P; Villers A
    Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Alpha-reductase inhibitors in diseases of the prostate.
    Carrasquillo RJ; Nealy SW; Wang DS
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):488-92. PubMed ID: 25268733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prostate cancer Research International: Active Surveillance study.
    Bangma CH; Bul M; Roobol M
    Curr Opin Urol; 2012 May; 22(3):216-21. PubMed ID: 22453333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of active surveillance for localized prostate cancer.
    Kim S; Dall'Era MA; Evans CP
    Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
    Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
    Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychological aspects of active surveillance.
    van den Bergh RC; Korfage IJ; Bangma CH
    Curr Opin Urol; 2012 May; 22(3):237-42. PubMed ID: 22357407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer overdiagnosis and overtreatment.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):203-9. PubMed ID: 22472510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
    Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
    Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Opportunities and risks of 5α reductase inhibitors in the medical management of Active surveillance for localized prostate cancer].
    Linares Espinos E; Carballido Rodriguez J
    Arch Esp Urol; 2014 Jun; 67(5):457-61. PubMed ID: 24914845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current status of active surveillance for prostate cancer.
    Pan DL; Samavedi S; Eldefrawy A; Manoharan M
    Postgrad Med; 2012 May; 124(3):50-8. PubMed ID: 22691899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer.
    Finelli A; Trottier G; Lawrentschuk N; Sowerby R; Zlotta AR; Radomski L; Timilshina N; Evans A; van der Kwast TH; Toi A; Jewett MA; Trachtenberg J; Fleshner NE
    Eur Urol; 2011 Apr; 59(4):509-14. PubMed ID: 21211899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economics of active surveillance for prostate cancer.
    Dall'Era MA
    Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active surveillance: oncologic outcome.
    Venderbos LD; Bokhorst LP; Bangma CH; Roobol MJ
    Curr Opin Urol; 2013 May; 23(3):268-72. PubMed ID: 23425994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsurgical Interventions to Prevent Disease Progression in Prostate Cancer Patients on Active Surveillance: A Systematic Review and Meta-analysis.
    Matsukawa A; Yanagisawa T; Bekku K; Parizi MK; Laukhtina E; Klemm J; Chiujdea S; Mori K; Kimura S; Miki J; Pradere B; Rivas JG; Gandaglia G; Kimura T; Kasivisvanathan V; Ploussard G; Cornford P; Shariat SF; Rajwa P
    Eur Urol Oncol; 2024 Jun; 7(3):376-400. PubMed ID: 38277189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.